Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Extracellular adenosine is elevated in cancer tissue, and it negatively regulates local immune responses. Adenosine production from extracellular ATP has attracted attention as a mechanism of regulatory T cell-mediated immune regulation. In this study, we examined whether small vesicles secreted by cancer cells, called exosomes, contribute to extracellular adenosine production and hence modulate immune effector cells indirectly. We found exosomes from diverse cancer cell types exhibit potent ATP- and 5'AMP-phosphohydrolytic activity, partly attributed to exosomally expressed CD39 and CD73, respectively. Comparable levels of activity were seen with exosomes from pleural effusions of mesothelioma patients. In such fluids, exosomes accounted for 20% of the total ATP-hydrolytic activity. Exosomes can perform both hydrolytic steps sequentially to form adenosine from ATP. This exosome-generated adenosine can trigger a cAMP response in adenosine A(2A) receptor-positive but not A(2A) receptor-negative cells. Similarly, significantly elevated cAMP was also triggered in Jurkat cells by adding exosomes with ATP but not by adding exosomes or ATP alone. A proportion of healthy donor T cells constitutively express CD39 and/or CD73. Activation of T cells by CD3/CD28 cross-linking could be inhibited by exogenously added 5'AMP in a CD73-dependent manner. However, 5'AMP converted to adenosine by exosomes inhibits T cell activation independently of T cell CD73 expression. This T cell inhibition was mediated through the adenosine A(2A) receptor. In summary, the data highlight exosome enzymic activity in the production of extracellular adenosine, and this may play a contributory role in negative modulation of T cells in the tumor environment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clayton et al. reported the expression of CD39, CD73, and eADO in MPM-derived exosome from pleural effusion, contributing to the inhibition of T cell functions [133].”
From Chronic Inflammation, Oxidative Stress and Metabolic Plasticity: Three Players Driving the Pro-Tumorigenic Microenvironment in Malignant Mesothelioma (2023) · cites this paper as [133]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Isolation and Characterization of Exosomes from Cell Culture Supernatants and Biological Fluids
Théry, C., Amigorena, S., Raposo, G., & Clayton, A. (2006) · Current Protocols in Cell Biology · doi:10.1002/0471143030.cb0322s30 · Cited by 5,766 · cited 1×
“To quantify the density of exosomes, we used a protocol similar to that previously described, based on ultracentrifugation on a linear sucrose gradient (36).”
MethodSelf-citationMembrane vesicles as conveyors of immune responses
Théry, C., Ostrowski, M., & Segura, E. (2009) · Nature Reviews Immunology · doi:10.1038/nri2567 · Cited by 3,882 · cited 1×
“immune-activating functions, there are also accumulating data pointing to varied suppressive effects (40).”
BackgroundB lymphocytes secrete antigen-presenting vesicles.
Raposo, G., Nijman, H. W., Stoorvogel, W., Liejendekker, R., Harding, C. V., Melief, C. J., & Geuze, H. J. (1996) · The Journal of experimental medicine · doi:10.1084/jem.183.3.1161 · Cited by 3,546 · cited 1×
“The density (g/ml) of each fraction was calculated from the published table in the Beckman Ultracentrifugation catalogue as described (37).”
MethodDeaglio, S., Dwyer, K. M., Gao, W., Friedman, D., Usheva, A., Erat, A., Chen, J.-F., Enjyoji, K., Linden, J., Oukka, M., et al. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20062512 · Cited by 2,470 · cited 5×
“These are double-positive for CD39 and CD73 in mice (12) and according to one report also in human (45).”
BackgroundInfluentialOhta, A., & Sitkovsky, M. (2001) · Nature · doi:10.1038/414916a · Cited by 1,334
Borsellino, G., Kleinewietfeld, M., Di Mitri, D., Sternjak, A., Diamantini, A., Giometto, R., Höpner, S., Centonze, D., Bernardi, G., Dell'Acqua, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-12-064527 · Cited by 1,286 · cited 3×
“Natural regulatory T cells of mice express both CD39 and CD73, whose coordinated enzymatic actions produce adenosine as a mechanism for immune suppression that is independent of IL-10 and TGF-b (12, 13).”
BackgroundAdenosine receptors: therapeutic aspects for inflammatory and immune diseases
Haskó, G., Linden, J., Cronstein, B., & Pacher, P. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2638 · Cited by 1,217 · cited 1×
“mechanisms involved in adenosine formation and subsequent signaling are therefore of considerable therapeutic interest (9).”
BackgroundA2A adenosine receptor protects tumors from antitumor T cells
Ohta, A., Gorelik, E., Prasad, S. J., Ronchese, F., Lukashev, D., Wong, M. K. K., Huang, X., Caldwell, S., Liu, K., Smith, P., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605251103 · Cited by 1,065 · cited 1×
“Adenosine also represses immune responses in the tumor microenvironment, assisting tumor immune evasion (7, 8).”
BackgroundMalignant effusions and immunogenic tumour-derived exosomes
Andre, F., Schartz, N. E., Movassagh, M., Flament, C., Pautier, P., Morice, P., Pomel, C., Lhomme, C., Escudier, B., Le Chevalier, T., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)09552-1 · Cited by 953 · cited 7×
“The cushion was collected and exosomes washed in PBS (32, 34, 35).”
MethodInfluentialExoCarta: A compendium of exosomal proteins and RNA
Mathivanan, S., & Simpson, R. J. (2009) · PROTEOMICS · doi:10.1002/pmic.200900351 · Cited by 873
Cited by
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Pegtel, D. M., & Gould, S. J. (2019) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-013118-111902 · Cited by 2,682
Molecular principles of metastasis: a hallmark of cancer revisited
Fares, J., Fares, M. Y., Khachfe, H. H., Salhab, H. A., & Fares, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0134-x · Cited by 2,379
Exosomes: biogenesis, biologic function and clinical potential
Zhang, Y., Liu, Y., Liu, H., & Tang, W. H. (2019) · Cell & Bioscience · doi:10.1186/s13578-019-0282-2 · Cited by 2,119
Classification, Functions, and Clinical Relevance of Extracellular Vesicles
van der Pol, E., Böing, A. N., Harrison, P., Sturk, A., & Nieuwland, R. (2012) · Pharmacological Reviews · doi:10.1124/pr.112.005983 · Cited by 1,754
“Exosomes from pleural effusion of patients with mesothelioma contained 20% of the total ATP-hydrolytic activity, indicating that exosomes may contribute to inhibition of T cells in the tumor environment by this mechanism (Clayton et al., 2011).”
BackgroundApplying extracellular vesicles based therapeutics in clinical trials – an ISEV position paper
Lener, T., Gimona, M., Aigner, L., Börger, V., Buzas, E., Camussi, G., Chaput, N., Chatterjee, D., Court, F. A., del Portillo, H. A., et al. (2015) · Journal of Extracellular Vesicles · doi:10.3402/jev.v4.30087 · Cited by 1,491
“and, coupled to this, to inhibit T cell effector functions (210,211,216).”
CD39 and CD73 in immunity and inflammation
Antonioli, L., Pacher, P., Vizi, E. S., & Haskó, G. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.03.005 · Cited by 1,263
“Recent mechanistic studies have shown that in addition to cell-associated CD39 and CD73, CD39and CD73-expressing cancer exosomes can also raise adenosine levels within the tumor microenvironment, thereby inhibiting T cell responses through stimulating A2A and A2B receptors [150].”
Cellular function and molecular structure of ecto-nucleotidases
Zimmermann, H., Zebisch, M., & Sträter, N. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9309-4 · Cited by 977
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.86 · Cited by 840
Consensus guidelines for the detection of immunogenic cell death
Kepp, O., Senovilla, L., Vitale, I., Vacchelli, E., Adjemian, S., Agostinis, P., Apetoh, L., Aranda, F., Barnaba, V., Bloy, N., et al. (2014) · OncoImmunology · doi:10.4161/21624011.2014.955691 · Cited by 832
Purinergic regulation of the immune system
Cekic, C., & Linden, J. (2016) · Nature Reviews Immunology · doi:10.1038/nri.2016.4 · Cited by 787
Exosomes in cancer: small particle, big player
Zhang, X., Yuan, X., Shi, H., Wu, L., Qian, H., & Xu, W. (2015) · Journal of Hematology & Oncology · doi:10.1186/s13045-015-0181-x · Cited by 780
“CD39, CD73 Bladder, colorectal, prostate, breast cancer cells T cells Induces adenosine production and inhibits T cell activation [101]”
BackgroundImmunity, inflammation and cancer: a leading role for adenosine
Antonioli, L., Blandizzi, C., Pacher, P., & Haskó, G. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3613 · Cited by 765
The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
Labani-Motlagh, A., Ashja-Mahdavi, M., & Loskog, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00940 · Cited by 751
“Moreover, exosomes displaying CD39 and CD73 released from tumor cells could generate adenosine to eliminate T cells (187).”
BackgroundMesenchymal stem cell: An efficient mass producer of exosomes for drug delivery
Yeo, R. W. Y., Lai, R. C., Zhang, B., Tan, S. S., Yin, Y., Teh, B. J., & Lim, S. K. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.07.001 · Cited by 746
Madrigal, M., Rao, K. S., & Riordan, N. H. (2014) · Journal of Translational Medicine · doi:10.1186/s12967-014-0260-8 · Cited by 615
“In recent years an explosion of interest in exosomes has occurred, with a wide variety of cells being reported to secrete these nanoparticles ranging from T cells [169,170], B cells [171,172], dendritic cells [173,174], tumor cells [175,176], neurons [177,178], oligodendrocytes [179], and placental cells [180].”
BackgroundExosomes─Nature’s Lipid Nanoparticles, a Rising Star in Drug Delivery and Diagnostics
Tenchov, R., Sasso, J. M., Wang, X., Liaw, W.-S., Chen, C.-A., & Zhou, Q. A. (2022) · ACS Nano · doi:10.1021/acsnano.2c08774 · Cited by 604
“…CD43, CD44, IGSF8, PTGFRN); syntenin; ALIX; heat shock proteins (HSP70, Hsp40/DnaJ proteins, Hsp90, Hsp20, Hsp27, α / β -crystallins) enzymes 27,120,143,144 ATPase, pyruvate kinase, fatty acid synthases, phosphatases, pyrophosphatases, calcium-binding annexins, phosphate transporters; RNA…”
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
“The molecules expressed on exosomes involved in regulating the immune response include FasL, TRAIL, membrane-bound TGF- , CD73, and galectins [36,43,44,63–67].”
BackgroundThe adenosine pathway in immuno-oncology
Allard, B., Allard, D., Buisseret, L., & Stagg, J. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0382-2 · Cited by 586
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
Tay, C., Tanaka, A., & Sakaguchi, S. (2023) · Cancer Cell · doi:10.1016/j.ccell.2023.02.014 · Cited by 580
Exosomes for drug delivery—A novel application for the mesenchymal stem cell
Lai, R. C., Yeo, R. W. Y., Tan, K. H., & Lim, S. K. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2012.08.008 · Cited by 546
“…(Fevrier et al., 2004), tumor cells (Wolfers et al., 2001), mesenchymal stem cells (Lai et al., 2010a), human embryonic kidney cells (Sokolova et al., 2011), various cancer cell lines (Clayton et al., 2011) and sperm (Sullivan et al., 2005), they were initially suspected to be culture artifacts.”
BackgroundSyn, N., Wang, L., Sethi, G., Thiery, J.-P., & Goh, B.-C. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2016.04.006 · Cited by 478
Big opportunities for small molecules in immuno-oncology
Adams, J. L., Smothers, J., Srinivasan, R., & Hoos, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4596 · Cited by 471
Classification of current anticancer immunotherapies
Galluzzi, L., Vacchelli, E., Pedro, J.-M. B.-S., Buqué, A., Senovilla, L., Baracco, E. E., Bloy, N., Castoldi, F., Abastado, J.-P., Agostinis, P., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2998 · Cited by 468
“Some human neoplasms express increased amounts of CD39 and/or CD73, reflecting the evolutionary advantage conferred to cancer cells by the stimulation of adenosine receptors [395, 396].”
BackgroundSelf-citationNakao, Y., Fukuda, T., Zhang, Q., Sanui, T., Shinjo, T., Kou, X., Chen, C., Liu, D., Watanabe, Y., Hayashi, C., et al. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2020.12.046 · Cited by 466
“Exosomal expression of CD73 was first identified in human cancer cells, which contributed to extracellular adenosine production, thereby leading to tumor growth and metastasis [44].”
BackgroundFates of CD8+ T cells in Tumor Microenvironment
Maimela, N. R., Liu, S., & Zhang, Y. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.11.004 · Cited by 459
Differentiation of tumour-promoting stromal myofibroblasts by cancer exosomes
Webber, J. P., Spary, L. K., Sanders, A. J., Chowdhury, R., Jiang, W. G., Steadman, R., Wymant, J., Jones, A. T., Kynaston, H., Mason, M. D., et al. (2015) · Oncogene · doi:10.1038/onc.2013.560 · Cited by 438
“Endothelial cell proliferation was assessed by thymidine incorporation assay as described (40), and viability quantified using Guava ViaCount TM flow cytometric system (Millipore).”
Self-citationTargeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
Vigano, S., Alatzoglou, D., Irving, M., Ménétrier-Caux, C., Caux, C., Romero, P., & Coukos, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00925 · Cited by 420
“In addition, CD39/CD73-bearing exosomes (69, 70), released by tumor cells (71), Tregs (72), and MDSCs (57, 73) further contribute to adenosine generation.”
BackgroundExosome removal as a therapeutic adjuvant in cancer
Marleau, A. M., Chen, C.-S., Joyce, J. A., & Tullis, R. H. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-134 · Cited by 411
CD39/CD73/A2AR pathway and cancer immunotherapy
Xia, C., Yin, S., To, K. K. W., & Fu, L. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01733-x · Cited by 399
Whiteside, T. L. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120265 · Cited by 388
“TEXs carry membrane-associated enzymes such as an ATP hydrolase, CD39 and a 5′-ectonucleotidase, CD73 [14].”
InfluentialCD73: a potent suppressor of antitumor immune responses
Beavis, P. A., Stagg, J., Darcy, P. K., & Smyth, M. J. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.02.009 · Cited by 355
Ye, S.-B., Li, Z.-L., Luo, D.-H., Huang, B.-J., Chen, Y.-S., Zhang, X.-S., Cui, J., Zeng, Y.-X., & Li, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2118 · Cited by 346
Transfer of extracellular vesicles during immune cell‐cell interactions
Gutiérrez‐Vázquez, C., Villarroya‐Beltri, C., Mittelbrunn, M., & Sánchez‐Madrid, F. (2013) · Immunological Reviews · doi:10.1111/imr.12013 · Cited by 323
“The effects of tumorderived EVs on T cells seem to be dependent on EV expression of FasL, TRAIL, membrane-bound TGFb, CD73, or galectins (34, 41, 116, 117, 119).”
BackgroundMoesta, A. K., Li, X.-Y., & Smyth, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0376-4 · Cited by 322
Purinergic signalling and cancer
Burnstock, G., & Di Virgilio, F. (2013) · Purinergic Signalling · doi:10.1007/s11302-013-9372-5 · Cited by 316
Targeting Cancer-Derived Adenosine:New Therapeutic Approaches
Young, A., Mittal, D., Stagg, J., & Smyth, M. J. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0341 · Cited by 310
“Release of tumor-derived exosomes expressing catalytically functional CD39 and CD73 represents an additional mechanism of tumor-mediated immunosuppressive adenosine generation (17).”
BackgroundCekic, C., Day, Y.-J., Sag, D., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3583 · Cited by 304
“), mononuclear MDSCs (Ly6C þ ), or granulocytic MDSCs (Ly6G þ ).”
InfluentialYegutkin, G. G. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.953627 · Cited by 299
“, 2003) and some cancer cells (Clayton et al., 2011) in the form of exosome- or microparticle-embedded enzyme.”
BackgroundMethodExtracellular vesicles in the tumor microenvironment: old stories, but new tales
Han, L., Lam, E. W.-F., & Sun, Y. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0980-8 · Cited by 294
Immunosuppressive Activities of Adenosine in Cancer
Allard, B., Beavis, P. A., Darcy, P. K., & Stagg, J. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.04.001 · Cited by 292
“Furthermore, an increasing number of studies now demonstrate that exosomes derived from CD39+CD73+ tumor cells [72], Tregs [73] or MSCs [69] can efficiently produce adenosine in the TME and suppress anti-tumor immunity.”
BackgroundWhat are regulatory T cells (Treg) regulating in cancer and why?
Whiteside, T. L. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.03.004 · Cited by 291
“Therefore, its presence on the surface of human Treg is difficult to demonstrate by conventional methods [64, 65].”
Recent advances on the role of tumor exosomes in immunosuppression and disease progression
Filipazzi, P., Bürdek, M., Villa, A., Rivoltini, L., & Huber, V. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.02.005 · Cited by 283
“In particular, functional CD39 and CD73 expressed by exosomes are capable of dephosphorylating exogenous ATP and 5′AMP to form adenosine, thus contributing to rise the adenosine levels within the microenvironment [53].”
BackgroundSchuler, P. J., Saze, Z., Hong, C.-S., Muller, L., Gillespie, D. G., Cheng, D., Harasymczuk, M., Mandapathil, M., Lang, S., Jackson, E. K., et al. (2014) · Clinical and Experimental Immunology · doi:10.1111/cei.12354 · Cited by 277
Smyth, L. A., Ratnasothy, K., Tsang, J. Y. S., Boardman, D., Warley, A., Lechler, R., & Lombardi, G. (2013) · European Journal of Immunology · doi:10.1002/eji.201242909 · Cited by 275
“Clayton et al. [23] have shown that CD39 and CD73, expressed by cancer exosomes, are involved in ATP and 5 -AMP-hydrolytic activity, respectively.”
BackgroundInfluentialEmerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy
Nam, G., Choi, Y., Kim, G. B., Kim, S., Kim, S. A., & Kim, I. (2020) · Advanced Materials · doi:10.1002/adma.202002440 · Cited by 267
Extracellular vesicles as circulating cancer biomarkers: opportunities and challenges
Lane, R. E., Korbie, D., Hill, M. M., & Trau, M. (2018) · Clinical and Translational Medicine · doi:10.1186/s40169-018-0192-7 · Cited by 245
“Tumour-EVs have been observed to suppress the activity of natural killer cells [50, 51] and T cells [52] and to promote the differentiation of myeloid derived suppressor cells [53, 54].”
BackgroundInvasion and metastasis in cancer: molecular insights and therapeutic targets
Li, Y., Liu, F., Cai, Q., Deng, L., Ouyang, Q., Zhang, X. H.-F., & Zheng, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02148-4 · Cited by 244
Functions and Therapeutic Roles of Exosomes in Cancer
Tickner, J. A., Urquhart, A. J., Stephenson, S.-A., Richard, D. J., & O’Byrne, K. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00127 · Cited by 242
“It has also been demonstrated that NK cells were unable to be activated, in response to Interleukin 2-mediated blocking by tumor-derived exosomes, and that tumor-derived exosomes suppress T-cells via induction of adenosine (53, 54).”
Bastid, J., Regairaz, A., Bonnefoy, N., Déjou, C., Giustiniani, J., Laheurte, C., Cochaud, S., Laprevotte, E., Funck-Brentano, E., Hemon, P., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0018 · Cited by 240
“389 Moreover, it has been reported that cancer exosomes released by various human cancer cell lines 390 express CD39 and CD73 on their surface and mediate immunosuppression via the generation of 391 adenosine (46), thereby supporting the finding that some cancer cells express both CD39 and CD73.”
Exosome: emerging biomarker in breast cancer
Jia, Y., Chen, Y., Wang, Q., Jayasinghe, U., Luo, X., Wei, Q., Wang, J., Xiong, H., Chen, C., Xu, B., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16684 · Cited by 234
“Tumor-derived exosomes expressed functional CD39 and CD73, which resulted in de-phosphorylation of exogenous ATP and 5’AMP to procedure adenosine, and rising adenosine can attenuate T cell function [93].”
BackgroundDanger signalling during cancer cell death: origins, plasticity and regulation
Garg, A. D., Martin, S., Golab, J., & Agostinis, P. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.48 · Cited by 226
Extracellular Vesicles and Their Roles in Cancer Progression
Chang, W.-H., Cerione, R. A., & Antonyak, M. A. (2021) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0759-6_10 · Cited by 224
Willingham, S. B., Ho, P. Y., Hotson, A., Hill, C., Piccione, E. C., Hsieh, J., Liu, L., Buggy, J. J., McCaffery, I., & Miller, R. A. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0056 · Cited by 222
“Previous studies have shown A2AR signaling inhibits the 84 effector function of multiple immune subsets, including T cells and NK cells (13, 22-25).”
BackgroundTumor-derived exosomes in cancer progression and treatment failure
Yu, S., Cao, H., Shen, B., & Feng, J. (2015) · Oncotarget · doi:10.18632/oncotarget.6022 · Cited by 216
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
Antonioli, L., Yegutkin, G. G., Pacher, P., Blandizzi, C., & Haskó, G. (2016) · Trends in Cancer · doi:10.1016/j.trecan.2016.01.003 · Cited by 213
Tumor-exosomes and leukocyte activation: an ambivalent crosstalk
Zech, D., Rana, S., Büchler, M. W., & Zöller, M. (2012) · Cell Communication and Signaling · doi:10.1186/1478-811x-10-37 · Cited by 217
“Tumor-exosomes affect T cells by inducing FAS-mediated apoptosis [14] and by enzymatic activity, which leads to extracellular adenosine production negatively modulating tumor infiltrating leukocytes (TIL) [15].”
Mastelic-Gavillet, B., Navarro Rodrigo, B., Décombaz, L., Wang, H., Ercolano, G., Ahmed, R., Lozano, L. E., Ianaro, A., Derré, L., Valerio, M., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0719-5 · Cited by 216
Bryniarski, K., Ptak, W., Jayakumar, A., Püllmann, K., Caplan, M. J., Chairoungdua, A., Lu, J., Adams, B. D., Sikora, E., Nazimek, K., et al. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.04.048 · Cited by 215
CD73-Deficient Mice Are Resistant to Carcinogenesis
Stagg, J., Beavis, P. A., Divisekera, U., Liu, M. C. P., Möller, A., Darcy, P. K., & Smyth, M. J. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0420 · Cited by 211
“CD73 expression on cancer exosomes can further suppress T-cell functions (13).”
BackgroundAdenosine A2B Receptor Blockade Slows Growth of Bladder and Breast Tumors
Cekic, C., Sag, D., Li, Y., Theodorescu, D., Strieter, R. M., & Linden, J. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101845 · Cited by 201
“expressed CD39 and CD73 that together increase extracellular adenosine production (2).”
BackgroundRegulation of the T Cell Response by CD39
Takenaka, M. C., Robson, S., & Quintana, F. J. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.04.009 · Cited by 207
ENTPD1/CD39 is a promising therapeutic target in oncology
Bastid, J., Cottalorda-Regairaz, A., Alberici, G., Bonnefoy, N., Eliaou, J.-F., & Bensussan, A. (2013) · Oncogene · doi:10.1038/onc.2012.269 · Cited by 202
Adenosine-A2A Receptor Pathway in Cancer Immunotherapy
Sun, C., Wang, B., & Hao, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837230 · Cited by 174
“A high concentration of adenosine further reduced the expression of ADA/CD26 complex, formed positive feedback, and promoted adenosine accumulation (39, 40) Moreover, a large number of experiments have proved that the concentration of adenosine in the tumor microenvironment is much higher than that in normal tissues (…”
BackgroundExtracellular Vesicle-Associated Proteins in Tissue Repair
Roefs, M. T., Sluijter, J. P. G., & Vader, P. (2020) · Trends in Cell Biology · doi:10.1016/j.tcb.2020.09.009 · Cited by 196
Zhang, F., Li, R., Yang, Y., Shi, C., Shen, Y., Lu, C., Chen, Y., Zhou, W., Lin, A., Yu, L., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.01.010 · Cited by 194
Exosomes as mediators of immune regulation and immunotherapy in cancer
Kugeratski, F. G., & Kalluri, R. (2021) · The FEBS Journal · doi:10.1111/febs.15558 · Cited by 192
Exosomes and their role in tumorigenesis and anticancer drug resistance
Milman, N., Ginini, L., & Gil, Z. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.07.003 · Cited by 192
Improved vaccine efficacy of tumor exosome compared to tumor lysate loaded dendritic cells in mice
Gu, X., Erb, U., Büchler, M. W., & Zöller, M. (2015) · International Journal of Cancer · doi:10.1002/ijc.29100 · Cited by 185
“TEX can induce FAS-mediated apoptosis(18) and negatively modulate tumor infiltrating leukocytes (TIL) via extracellular adenosine production.(19) NK activity becomes impaired via TEX inhibiting activation of Stat5, Jak3, cyclinD3 expression and perforin release(20) or by blocking NKG2D as far as TEX express relevant r…”
BackgroundTherapeutic and diagnostic applications of extracellular vesicles
Stremersch, S., De Smedt, S. C., & Raemdonck, K. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.07.054 · Cited by 186
Obata, Y., Kita, S., Koyama, Y., Fukuda, S., Takeda, H., Takahashi, M., Fujishima, Y., Nagao, H., Masuda, S., Tanaka, Y., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.99680 · Cited by 181
Adenosine A2A Receptors Intrinsically Regulate CD8+ T Cells in the Tumor Microenvironment
Cekic, C., & Linden, J. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3581 · Cited by 174
“3 INTRODUCTION Solid tumors produce high concentrations of adenosine in response to hypoxia, cell necrosis and the rapid metabolism of extracellular adenine nucleotides by ectonucleotidases expressed on tumor cells, tumor cell exosomes and T regulatory cells (1-4).”
Exosomes in Inflammation and Inflammatory Disease
Chan, B. D., Wong, W., Lee, M. M., Cho, W. C., Yee, B. K., Kwan, Y. W., & Tai, W. C. (2019) · PROTEOMICS · doi:10.1002/pmic.201800149 · Cited by 166
Dominant immunosuppression of dendritic cell function by prostate‐cancer‐derived exosomes
Salimu, J., Webber, J., Gurney, M., Al‐Taei, S., Clayton, A., & Tabi, Z. (2017) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2017.1368823 · Cited by 165
“As it has been previously shown that exosomes express membrane-bound CD73 [7], we wanted to confirm that CD73 expression on DC was not due to exosome binding.”
BackgroundSelf-citationDi Pace, A., Tumino, N., Besi, F., Alicata, C., Conti, L., Munari, E., Maggi, E., Vacca, P., & Moretta, L. (2020) · Cancers · doi:10.3390/cancers12030661 · Cited by 169
“Thus, Treg cells have been shown to secrete exosomes expressing CD73 that inhibit proliferation of CD4+ T cells [23].”
BackgroundCeramide and Exosomes: A Novel Target in Cancer Biology and Therapy
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.05.004 · Cited by 161
Műzes, G., & Sipos, F. (2022) · Cells · doi:10.3390/cells11152300 · Cited by 168
“, tumor-infiltrating T-cell function), tumor cells with this unique capability are capable of suppressing and modulating inflammation-inducing activity [170,171].”
BackgroundCD73 and adenosine generation in the creation of regulatory microenvironments
Regateiro, F. S., Cobbold, S. P., & Waldmann, H. (2012) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2012.04623.x · Cited by 166
Erratum: Targeting immunosuppressive adenosine in cancer
Vijayan, D., Young, A., Teng, M. W. L., & Smyth, M. J. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.110 · Cited by 167
Extracellular vesicles as modulators of the cancer microenvironment
Webber, J. P., Yeung, V., & Clayton, A. (2015) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2015.01.013 · Cited by 172
Self-citationTargeting CD73 to augment cancer immunotherapy
Roh, M., Wainwright, D. A., Wu, J. D., Wan, Y., & Zhang, B. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.07.001 · Cited by 161
“Interestingly, CD73 together with CD39 were found on exosomes isolated from mesothelioma patients [46] and CD73+ exosome suppressed immune cell function [46,47].”
BackgroundTargeting the CD73-adenosine axis in immuno-oncology
Allard, D., Chrobak, P., Allard, B., Messaoudi, N., & Stagg, J. (2019) · Immunology Letters · doi:10.1016/j.imlet.2018.05.001 · Cited by 158
Circulating RNAs as new biomarkers for detecting pancreatic cancer
Kishikawa, T. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i28.8527 · Cited by 154
Cd73: An Emerging Checkpoint for Cancer Immunotherapy
Chen, S., Wainwright, D. A., Wu, J. D., Wan, Y., Matei, D. E., Zhang, Y., & Zhang, B. (2019) · Immunotherapy · doi:10.2217/imt-2018-0200 · Cited by 162
“Although the full role of CD73 on human Tregs is still being characterized, it is generally accepted that they generate adenosine through paracrine interaction(s) with local CD73-expressing cells and/or tumor-derived exosomes [70,71].”
BackgroundTumor-derived exosomes: the next generation of promising cell-free vaccines in cancer immunotherapy
Naseri, M., Bozorgmehr, M., Zöller, M., Ranaei Pirmardan, E., & Madjd, Z. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1779991 · Cited by 149
“The expression of CD73, CD39 immunoregulatory proteins, TGF-β1 cytokine, and galectin-1 (Gal-1) in TEXs can induce a suppressive phenotype in CD8 and CD4 T cells.(130,141,142) In addition, TEXs impair the lymphocyte response to IL-2(143) and have been shown to induce IL-8 production in epithelial cells suppressing T c…”
BackgroundSchneider, E., Winzer, R., Rissiek, A., Ricklefs, I., Meyer‐Schwesinger, C., Ricklefs, F. L., Bauche, A., Behrends, J., Reimer, R., Brenna, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26134-w · Cited by 158
CD73 as a potential opportunity for cancer immunotherapy
Ghalamfarsa, G., Kazemi, M. H., Mohseni, S. R., Masjedi, A., Hojjat‐Farsangi, M., Azizi, G., Yousefi, M., & Jadidi‐Niaragh, F. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1559829 · Cited by 158
Lazar, I., Clement, E., Ducoux‐Petit, M., Denat, L., Soldan, V., Dauvillier, S., Balor, S., Burlet‐Schiltz, O., Larue, L., Muller, C., et al. (2015) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12380 · Cited by 156
“Among these molecules, galectins (LGALS1/LEG1 and LGALS3/LEG3) and 5’-nucleotidase (NT5E/5NTD also known as CD73) are well-known tumor exosomal proteins (Atay et al., 2014; Clayton et al., 2011).”
BackgroundZhang, C., Qin, C., Dewanjee, S., Bhattacharya, H., Chakraborty, P., Jha, N. K., Gangopadhyay, M., Jha, S. K., & Liu, Q. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01932-0 · Cited by 148
“This event could arise from epigenetic alterations induced by TDSEVs within T cells [129].”
BackgroundExpression of CD39 on activated T cells impairs their survival in older individuals
Fang, F., Yu, M., Cavanagh, M. M., Hutter Saunders, J., Qi, Q., Ye, Z., Le Saux, S., Sultan, W., Turgano, E., Dekker, C. L., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.01.002 · Cited by 138
“Finally, AMP generated by CD39 is further cleaved to adenosine, likely by CD73- containing exosomes in the culture (Clayton et al., 2011).”
InfluentialTumor-derived exosomes promote angiogenesis via adenosine A2B receptor signaling
Ludwig, N., Yerneni, S. S., Azambuja, J. H., Gillespie, D. G., Menshikova, E. V., Jackson, E. K., & Whiteside, T. L. (2020) · Angiogenesis · doi:10.1007/s10456-020-09728-8 · Cited by 140
Acquisition of new tumor cell properties by MSC-derived exosomes
YANG, Y., BUCAN, V., BAEHRE, H., VON DER OHE, J., OTTE, A., & HASS, R. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3001 · Cited by 129
On the mechanism of anti-CD39 immune checkpoint therapy
Allard, D., Allard, B., & Stagg, J. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000186 · Cited by 142
The contribution of tumour-derived exosomes to the hallmarks of cancer
Meehan, K., & Vella, L. J. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1092496 · Cited by 129
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go?
Kumar, V. (2012) · Purinergic Signalling · doi:10.1007/s11302-012-9349-9 · Cited by 145
Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment
Ito, K., Stannard, K. A., Gabutero, E., Clark, A. M., Neo, S., Onturk, S., Blanchard, H., & Ralph, S. J. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9388-2 · Cited by 148
Role of TGF-β Signaling in Generation of CD39+CD73+ Myeloid Cells in Tumors
Ryzhov, S. V., Pickup, M. W., Chytil, A., Gorska, A. E., Zhang, Q., Owens, P., Feoktistov, I., Moses, H. L., & Novitskiy, S. V. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400578 · Cited by 118
“cells (15, 16) or even exosomes (17), have attracted much attention lately due to their involvement in ATP–CD39–CD73–adenosine pathway, which can shift the balance from tumor-suppressive extracellular ATP toward tumor-promoting extracellular adenosine.”
The role of exosomes in tumor progression and metastasis (Review)
Suchorska, W. M., & Lach, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4507 · Cited by 131
Production of Adenosine by Ectonucleotidases: A Key Factor in Tumor Immunoescape
Ghiringhelli, F., Bruchard, M., Chalmin, F., & Rébé, C. (2012) · BioMed Research International · doi:10.1155/2012/473712 · Cited by 133
“Ectonucleotidase expression on tumor cells and on tumor exosomes (small vesicles secreted by cancer cells) may increase local concentrations of adenosine and could blunt the antitumoral immune response [73, 74].”
Background
Metadata
- Authors
- Clayton, A., Al-Taei, S., Webber, J., Mason, M. D., & Tabi, Z.
- Affiliations
- Velindre Cancer Centre (GB)
- Department of Pharmacology, Radiology and Oncology, School of Medicine, Cardiff University, Velindre Cancer Centre , Whitchurch, Cardiff CF14 2TL ,
- Corresponding author
- Clayton, Aled
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-07
- Volume
- 187
- Issue
- 2
- Pages
- 676-683
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2153092839
- Cited by
- 540
- References
- 49
- Citations by year
- 2026: 18 · 2025: 30 · 2024: 31 · 2023: 38 · 2022: 53 · 2021: 50 · 2020: 61 · 2019: 37 · 2018: 36 · 2017: 29 · 2016: 30 · 2015: 24 · 2014: 33 · 2013: 26 · 2012: 40
- FWCI
- 23.02
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Physiology › Adenosine and Purinergic Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Extracellular vesicles in disease
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Biochemical and Molecular Research
- Keywords
- tumor-derived exosomes, CD39, CD73, extracellular adenosine, ATP hydrolysis, 5'-AMP, adenosine A2A receptor, cAMP signaling, T cell activation inhibition, tumor immunosuppression, mesothelioma, extracellular vesicles
- MeSH terms
- Adenosine, Adenosine Monophosphate, Adenosine Triphosphate, Apyrase, Humans, Hydrolysis, Mesothelioma, Phosphorylation, Pleural Neoplasms, Down-Regulation, Antigens, CD, 5'-Nucleotidase, Caco-2 Cells, Jurkat Cells, Cell Line, Tumor, T-Lymphocytes, Regulatory, Exosomes, GPI-Linked Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.